XORTX Therapeutics (XRTX)
(Delayed Data from NSDQ)
$1.75 USD
-0.05 (-2.78%)
Updated Jul 30, 2024 03:55 PM ET
After-Market: $1.75 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XRTX 1.75 -0.05(-2.78%)
Will XRTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for XRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for XRTX
XORTX Therapeutics Plans Major Warrant Repricing
XORTX to Present at BIO International Convention 2024
XORTX Therapeutics Showcases Progress at BIO 2024
XRTX Stock Earnings: XORTX Therapeutics Reported Results for Q1 2024
XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO